(Q27014110)

20 August 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

11 November 2019

1 reference

13 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ismael Capel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mercedes Rigla

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Lara Albert

series ordinal

2

2 references

Crossref

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

2014

1 reference

Drug Design, Development and Therapy

18 September 2014

6 references

19 March 2019

24 March 2019

20 August 2019

17 September 2019

11 November 2019

13 November 2019

8 references

19 March 2019

24 March 2019

20 August 2019

17 September 2019

11 November 2019

13 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

8

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

1419-1427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

3 June 2020

copyright license

6 references

19 March 2019

24 March 2019

20 August 2019

17 September 2019

11 November 2019

13 November 2019

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Pharmacotherapies for obesity: past, current, and future therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Body-Mass Index and Mortality among 1.46 Million White Adults

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

New and emerging drug molecules against obesity.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

New medications for obesity management: changing the landscape of obesity treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

New pharmacological approaches for obesity management.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Reducing the risk of obesity: defining the role of weight loss drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Pharmacologic treatment options for obesity: what is old is new again

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Recent advancements in drug treatment of obesity.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Anti-obesity drugs: past, present and future

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

ACS chemical neuroscience molecule spotlight on contrave

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Obesity and severe obesity forecasts through 2030.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Recent advances in the pathophysiology and pharmacological treatment of obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Anti-obesity drugs: a review about their effects and their safety

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

A review of late-stage CNS drug candidates for the treatment of obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

What is the prognosis for new centrally-acting anti-obesity drugs?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone/bupropion: an investigational combination for weight loss and maintenance.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Combination therapy with naltrexone and bupropion for obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Current and future drug targets in weight management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Pharmacological management of appetite expression in obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Drugs in the pipeline for the obesity market

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone for the treatment of obesity: review and update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Central control of body weight and appetite

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Pharmacological therapies for obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Opioid peptides and the control of human ingestive behaviour

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Opiate antagonists and eating behavior in humans: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Effects of long-term therapy with naltrexone on body weight in obesity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

An opioid antagonist, naltrexone, reduces preference for sucrose in humans

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Effect of naltrexone on food intake, hunger, and satiety in obese men.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Suppression of appetitive behavior in the rat by naloxone: Lack of effect of prior morphine dependence

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Therapies for obesity and medication-associated weight gain

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Prevalence of obesity in the United States, 2009-2010.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

28 November 2018

What cost weight loss?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Bupropion/naltrexone fixed-dose combination for the treatment of obesity

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Hypothalamic opioid-melanocortin appetitive balance and addictive craving

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Is cardiometabolic risk improved by weight-loss drugs?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Annual medical spending attributable to obesity: payer-and service-specific estimates

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Rational design of a combination medication for the treatment of obesity

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

To eat or not to eat - how the gut talks to the brain

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174046

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

28 November 2018

1 reference

12 December 2020

Drug Treatment of Obesity

1 reference

12 December 2020

A controlled trial of naltrexone in obese humans

1 reference

12 December 2020

New obesity pill: new hopes, old fears

1 reference

12 December 2020

Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR

1 reference

12 December 2020

High-dose naltrexone therapy and dietary counseling for obesity

1 reference

12 December 2020

Identifiers

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

release_nn7t3uiq3jbdpnf62rurjg7bhq

3 June 2020

Fatcat ID

0 references

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

PubMed publication ID

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25258511%20AND%20SRC:MED&resulttype=core&format=json